China’s Envision links with global drug giants to spur ‘net zero healthcare systems’
Deal unveiled at Davos summit will allow healthcare companies to decarbonise their operations, says wind power giant
China's Envision Energy has agreed to deliver 200GWh of green power annually to five global pharmaceuticals companies to help decarbonise healthcare systems.
Envision announced today that it has signed a three-year supply agreement with UK-Swedish company AstraZeneca, Denmark’s Novo Nordisk and the Swiss trio of Novartis, Lonza and Roche.
Envision said the deal – announced during the annual World Economic Forum summit in Davos, Switzerland – will help “accelerate the transition to net zero health systems.”
The 200GWh of green power supply will reduce carbon dioxide equivalent emissions by 120,000 tons annually, said Envision, comparable to taking 25,000 cars off the road.
“This collaboration unlocks a new way for more companies in the healthcare supply chain to decarbonise their operations,” it said.
Envision has emerged as one of China's leading manufacturers of wind turbines, but the company also designs and manufactures energy storage systems, green hydrogen products and is expanding into the fast-growing market for artificial intelligence platforms.
In its statement on the agreement with the European-based pharmaceutical giants Envision stated that it also assists "partners in achieving net zero goals through its innovative consultation, digital solutions, and power purchase agreements , integrating existing regulatory and technology frameworks."
(Copyright)